PDCD1 and neoplasm: Another phase I clinical trial testing the safety and maximum tolerated dose of the STING agonist TAK-500, alone or with pembrolizumab, a monoclonal antibody targeting PD-1, is currently recruiting patients with locally advanced or metastatic solid tumors, however, MPNST is not one of the eligible tumor types (ClinicalTrials.gov ID, NCT05070247).